Hosking D J, Heller S R
Eur J Clin Pharmacol. 1986;31(1):27-31. doi: 10.1007/BF00870981.
The renal effect of calcitonin (independent of changes due to variations in sodium excretion) was quantitated in malignancy associated hypercalcaemia. There was considerable inter- and intra-patient variability in response but this was unaffected by tumour type. Humoral hypercalcaemia tended to be resistant to control. In responsive patients the renal effects of calcitonin unlike those described in bone did not diminish with time.
在恶性肿瘤相关性高钙血症中,对降钙素的肾脏效应(独立于因钠排泄变化引起的改变)进行了定量研究。患者之间和患者自身的反应存在相当大的变异性,但这不受肿瘤类型的影响。体液性高钙血症往往难以控制。在有反应的患者中,降钙素对肾脏的作用与在骨骼中所描述的不同,不会随时间而减弱。